小細胞肺がん治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Small-Cell Lung Cancer - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0631
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:1225
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Small-Cell Lung Cancer – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer – Pipeline Review, H2 2019, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Small-Cell Lung Cancer – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 61, 43, 6, 39, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Small-Cell Lung Cancer – Overview
Small-Cell Lung Cancer – Therapeutics Development
Small-Cell Lung Cancer – Therapeutics Assessment
Small-Cell Lung Cancer – Companies Involved in Therapeutics Development
Small-Cell Lung Cancer – Drug Profiles
Small-Cell Lung Cancer – Dormant Projects
Small-Cell Lung Cancer – Discontinued Products
Small-Cell Lung Cancer – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Small-Cell Lung Cancer, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Products under Development by Companies, H2 2019 (Contd..7), H2 2019
Products under Development by Companies, H2 2019 (Contd..8), H2 2019
Products under Development by Companies, H2 2019 (Contd..9), H2 2019
Products under Development by Companies, H2 2019 (Contd..10), H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2019

【掲載企業】

AbbVie Inc
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
Aeglea BioTherapeutics Inc
Akeso Biopharma Inc
Allogene Therapeutics Inc
Altor Bioscience LLC
Amgen Inc
Andarix Pharmaceuticals Inc
Apollomics Inc
Aposense Ltd
Aprea Therapeutics AB
Ascenta Therapeutics Inc
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Auransa Inc
Autolus Therapeutics Plc
Bavarian Nordic A/S
BeiGene Ltd
Beta Pharma Inc
BeyondSpring Inc
Biogenera SpA
BioLineRx Ltd
BioNTech SE
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Carrick Therapeutics UK Ltd
Celldex Therapeutics Inc
Checkpoint Therapeutics Inc
Chiome Bioscience Inc
Chipscreen Biosciences Ltd
Coherent Biopharma
Cotinga Pharmaceuticals Inc
CSPC Pharmaceutical Group Ltd
CStone Pharmaceuticals Co Ltd
Cumberland Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Eisai Co Ltd
Eli Lilly and Co
EpicentRx Inc
Esanex Inc
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
G1 Therapeutics Inc
GlaxoSmithKline Plc
Guangdong Zhongsheng Pharmaceutical Co Ltd
Hanmi Pharmaceuticals Co Ltd
Harpoon Therapeutics Inc
Hillstream BioPharma Inc
Horizon Therapeutics PLC
Hutchison MediPharma Ltd
ImmunityBio Inc
Immunocore Ltd
Immunomedics Inc
ImmunSYS Inc
Incyte Corp
Innovent Biologics Inc
Ipsen SA
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Karyopharm Therapeutics Inc
Lee's Pharmaceutical Holdings Ltd
Lixte Biotechnology Holdings Inc
MabVax Therapeutics Holdings Inc
Merck & Co Inc
Merck KGaA
Moderna Therapeutics Inc
Mologen AG
MultiVir Inc
Mundipharma EDO GmbH
Nektar Therapeutics
NewBio Therapeutics Inc
NewLink Genetics Corp
Ningbo Wenda Pharma
Nippon Kayaku Co Ltd
Northlake International LLC
Novartis AG
NOX Pharmaceuticals Inc
OncoFusion Therapeutics Inc
Ono Pharmaceutical Co Ltd
Oryzon Genomics SA
Oxford BioTherapeutics Ltd
Pfizer Inc
Phanes Therapeutics Inc
Pharma Mar SA
Plexxikon Inc
Plus Therapeutics Inc
Rafael Pharmaceuticals Inc
Recombio SL
Rexahn Pharmaceuticals Inc
Rgenix Inc
SciTech Development LLC
Seattle Genetics Inc
SELLAS Life Sciences Group Inc
Seneca Therapeutics Inc
Shanghai Henlius Biotech Inc
Shanghai Junshi Bioscience Co Ltd
Sichuan J.Z. Bio-chemical Science and Technology Development Co Ltd
Sierra Oncology Inc
Sorrento Therapeutics Inc
Sound Biologics
Starpharma Holdings Ltd
Sun Pharma Advanced Research Company Ltd
Syros Pharmaceuticals Inc
Tactical Therapeutics Inc
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Targovax ASA
Tarveda Therapeutics Inc
Telomium SAS
Tmunity Therapeutics Inc
Trillium Therapeutics Inc
Trovagene Inc
United Therapeutics Corp
Woomera Therapeutics Inc
Xbrane Biopharma AB
Xcovery Holding Company LLC
Xencor Inc
Y-Biologics
Zensun (Shanghai) Sci & Tech Co Ltd


【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[小細胞肺がん治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆